Stefan Oelrich, president of Bayer’s pharmaceutical division and head of the EU’s pharmaceutical lobby EFPIA, emphasizes the urgent need for capital market reform in Europe to support biotech development. He advocates for a Nasdaq-like platform to raise capital for biotech, highlighting the limited venture capital available in Europe and the migration of innovations to the US. Oelrich's comments precede the EU’s Life Sciences Strategy, which aims to enhance Europe's biotech position but lacks a strong focus on completing the Capital Markets Union. He calls for better allocation of capital and suggests redirecting pension funds towards venture investments. Teljes cikk (Euronews.com)